Status:
UNKNOWN
Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pancreatic Cancer
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Venous Thromboembolic Events (ETVs) are the second leading cause of death (9.2% of causes of death) in cancer patients after tumor progression (1). Indeed, cancer is associated with a 4 to 7-fold risk...
Detailed Description
The NETs will be detected and quantified by CMF on the remaining EDTA tube collected to perform the blood count (NFS), using the method in place in the laboratory, adapted from the method initially de...
Eligibility Criteria
Inclusion
- Male or Female over 18 years of age (≥18),
- Patient with pancreatic, gastric or colorectal cancer,
- Patient with a high risk of ETV,
- Patient on the first line of treatment or relapsing after a period of complete remission,
- Patient affiliated to a social security system or CMU.
Exclusion
- Patient who has had an ETV in the 3 months prior to inclusion,
- Patient with a life expectancy of less than 3 months,
- Patient with an anticoagulation placement,
- Known pregnant or breastfeeding woman,
- Patient under guardianship or curatorship.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04294589
Start Date
July 1 2019
End Date
December 1 2020
Last Update
November 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ambroise Pare Hospital
Boulogne-Billancourt, Haut de Seine, France, 92100